Claiming a win where Gilead failed, Sierra touts PhIII success in a JAK inhibitor — and is ready to take it to the FDA
About three and a half years ago, Sierra Oncology took on a formerly failed JAK inhibitor candidate from Gilead, believing it could succeed where the bigger biopharma failed. On Tuesday, the biotech revealed the program passed a Phase III test.
Sierra unveiled positive topline data for momelotinib, saying the experimental drug met its primary endpoint and both secondaries in myelofibrosis patients who are symptomatic, anemic and were previously treated with an FDA-approved JAK inhibitor. With the new data in hand, Sierra now plans to submit an NDA sometime in the second quarter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.